Takeda Pharmaceutical Free Cash Flow (FCF) History (TAK)

Takeda Pharmaceutical reported ¥856.39B in free cash flow for fiscal 2025, an increase of 58.32% from the previous fiscal year, with a free cash flow margin of 18.69%.

View full Takeda Pharmaceutical company overview

Takeda Pharmaceutical free cash flow by year

Takeda Pharmaceutical annual free cash flow

2017

2018

2019

2020

2021

2022

2023

2024

2025

Fiscal year	Period ended	Free cash flow	Change	Growth	FCF margin
2025	2025-03-31	¥856.39B	¥315.46B	+58.32%	+18.69%
2024	2024-03-31	¥540.92B	−¥295.57B	−35.33%	+12.69%
2023	2023-03-31	¥836.50B	−¥163.35B	−16.34%	+20.77%
2022	2022-03-31	¥999.85B	¥100.13B	+11.13%	+28.01%
2021	2021-03-31	¥899.73B	¥357.06B	+65.80%	+28.14%
2020	2020-03-31	¥542.67B	¥291.87B	+116.37%	+16.49%
2019	2019-03-31	¥250.80B	−¥60.05B	−19.32%	+11.96%
2018	2018-03-31	¥310.85B	¥111.15B	+55.66%	+17.56%
2017	2017-03-31	¥199.70B	—	—	+11.53%

Takeda Pharmaceutical free cash flow growth trends

Over the last five reported fiscal years, free cash flow grew from ¥542.67B to ¥856.39B, a compound annual growth rate of 9.55%.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Takeda Pharmaceutical filings at SEC.gov ↗